<DOC>
	<DOCNO>NCT01393106</DOCNO>
	<brief_summary>This study evaluate efficacy safety idelalisib participant relapse refractory Hodgkin Lymphoma ( HL ) . The primary objective ass overall response rate . Eligible participant initiate oral therapy idelalisib start dose 150 mg twice daily . Treatment idelalisib continue tumor progression unacceptable toxicity .</brief_summary>
	<brief_title>Safety Efficacy Idelalisib Relapsed Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Age ≥ 12 year Karnofsky performance score ≥ 60 ( Eastern Cooperative Oncology Group ( ECOG ) performance score 0 , 1 , 2 ) Histologically confirm diagnosis classic HL ( ie , nodular sclerosis , mixed cellularity , lymphocyte deplete , lymphocyte rich type ) Nodal HL show fluorodeoxyglucose ( FDG ) avidity ( defined focal diffuse FDG uptake background location incompatible normal anatomy physiology ) , measurable ( define presence ≥ 1 nodal lesion measure ≥ 2 cm single dimension assess CT , PET/CT , magnetic resonance imaging ( MRI ) ) Relapsed refractory HL prior myeloablative therapy autologous stem cell transplantation ( ASCT ) ≥ 2 prior chemotherapycontaining regimen curative option conventional therapy Discontinuation radiotherapy chemotherapy treatment HL great equal 3 week initiation study treatment discontinuation radioimmunotherapy HL ( Visit 2 ) All acute toxic effect ( exclude alopecia , neurotoxicity , anemia ) prior antitumor therapy resolve Grade ≤ 2 initiation study treatment ( Visit 2 ) For men woman childbearing potential willingness abstain sexual intercourse employ effective method contraception study drug administration followup period Willingness ability provide write informed consent comply protocol requirement Known active central nervous system leptomeningeal lymphoma History nonlymphoma malignancy except follow : adequately treat local basal cell squamous cell carcinoma skin , cervical carcinoma situ , superficial bladder cancer , localize prostate cancer , adequately treat Stage 1 2 cancer currently complete remission , cancer complete remission ≥ 5 year Evidence ongoing systemic bacterial , fungal , viral infection ( exclude viral upper respiratory tract infection ) time initiation study treatment ( Visit 2 ) Pregnancy breastfeed Ongoing alcohol drug addiction Known history druginduced liver injury , chronic active hepatitis C virus ( HCV ) , chronic active hepatitis B virus ( HBV ) , alcoholic liver disease , nonalcoholic steatohepatitis , primary biliary cirrhosis , ongoing extrahepatic obstruction cause stone , cirrhosis liver portal hypertension History prior allogeneic bone marrow progenitor cell solid organ transplantation Ongoing immunosuppressive therapy , include systemic corticosteroid . Prior therapy idelalisib Exposure another investigational drug within 3 week prior start study treatment Concurrent participation another therapeutic treatment trial Prior ongoing clinically significant illness , medical condition , surgical history , physical finding , ECG finding , laboratory abnormality , investigator 's opinion , could affect safety patient ; alter absorption , distribution , metabolism excretion study drug ; impair assessment study result Prior therapy drug inhibits Akt , Bruton tyrosine kinase ( BTK ) , Janus kinase ( JAK ) , mammalian target rapamycin ( mTOR ) , phosphatidylinositol 3 kinase ( PI3K ) ( include idelalisib ) , spleen tyrosine kinase ( SYK )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HL</keyword>
	<keyword>idelalisib</keyword>
	<keyword>CAL-101</keyword>
	<keyword>GS-1101</keyword>
	<keyword>PI3K</keyword>
</DOC>